JP2015502926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502926A5 JP2015502926A5 JP2014541555A JP2014541555A JP2015502926A5 JP 2015502926 A5 JP2015502926 A5 JP 2015502926A5 JP 2014541555 A JP2014541555 A JP 2014541555A JP 2014541555 A JP2014541555 A JP 2014541555A JP 2015502926 A5 JP2015502926 A5 JP 2015502926A5
- Authority
- JP
- Japan
- Prior art keywords
- tautomer
- stereoisomer
- proportions
- mixture
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011118830A DE102011118830A1 (de) | 2011-11-18 | 2011-11-18 | Morpholinylbenzotriazine |
| DE102011118830.8 | 2011-11-18 | ||
| PCT/EP2012/004542 WO2013072015A1 (de) | 2011-11-18 | 2012-10-30 | Morpholinylbenzotriazine zur anwendung in der krebstherapie |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502926A JP2015502926A (ja) | 2015-01-29 |
| JP2015502926A5 true JP2015502926A5 (enExample) | 2015-12-24 |
| JP6096792B2 JP6096792B2 (ja) | 2017-03-15 |
Family
ID=47143824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541555A Expired - Fee Related JP6096792B2 (ja) | 2011-11-18 | 2012-10-30 | 癌治療における使用のためのモルホリニルベンゾトリアジン |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9187469B2 (enExample) |
| EP (1) | EP2780332B1 (enExample) |
| JP (1) | JP6096792B2 (enExample) |
| KR (1) | KR20140097391A (enExample) |
| CN (1) | CN103930408B (enExample) |
| AU (1) | AU2012339196B2 (enExample) |
| BR (1) | BR112014011805A2 (enExample) |
| CA (1) | CA2856103C (enExample) |
| DE (1) | DE102011118830A1 (enExample) |
| DK (1) | DK2780332T3 (enExample) |
| EA (1) | EA201400595A1 (enExample) |
| ES (1) | ES2572605T3 (enExample) |
| HK (1) | HK1199875A1 (enExample) |
| HR (1) | HRP20160495T1 (enExample) |
| HU (1) | HUE027577T2 (enExample) |
| IL (1) | IL232577A (enExample) |
| IN (1) | IN2014KN01287A (enExample) |
| MX (1) | MX2014005838A (enExample) |
| PL (1) | PL2780332T3 (enExample) |
| RS (1) | RS54768B1 (enExample) |
| SG (1) | SG11201402206YA (enExample) |
| SI (1) | SI2780332T1 (enExample) |
| WO (1) | WO2013072015A1 (enExample) |
| ZA (1) | ZA201404438B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201406584TA (en) | 2012-04-24 | 2014-11-27 | Vertex Pharma | Dna-pk inhibitors |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| KR102411227B1 (ko) | 2013-10-17 | 2022-06-21 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제로서 (s)-n-메틸-8-(1-((2'-메틸-[4,5'-비피리미딘]-6-일)아미노)프로판-2-일)퀴놀린-4-카복스아미드 및 이의 듀테로화된 유도체의 공결정 |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| CN107793373B (zh) * | 2017-10-31 | 2019-09-17 | 广西师范大学 | 2-取代苯并三嗪酮衍生物及其制备方法 |
| BR112020014140A2 (pt) | 2018-01-17 | 2020-12-01 | Vertex Pharmaceuticals Incorporated | inibidores de dna-pk |
| US12269804B2 (en) | 2018-01-17 | 2025-04-08 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| WO2019143678A1 (en) * | 2018-01-17 | 2019-07-25 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| ES3055187T3 (en) | 2019-11-01 | 2026-02-10 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
| KR20240024926A (ko) | 2021-06-24 | 2024-02-26 | 신젠타 크롭 프로텍션 아게 | 살충제로서의 2-[3-[1[(퀴나졸린-4-일)아미노]에틸]피라진-2-일]티아졸-5-카르보니트릴 유도체 및 유사한 화합물 |
| EP4543873A1 (en) | 2022-06-21 | 2025-04-30 | Syngenta Crop Protection AG | Pesticidally active fused bicyclic heteroaromatic compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9107070A (pt) | 1990-11-06 | 1994-05-31 | Pfizer | Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral. |
| EP1187633A4 (en) | 1999-04-08 | 2005-05-11 | Arch Dev Corp | USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY |
| WO2002020500A2 (en) * | 2000-09-01 | 2002-03-14 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
| CN101230045B (zh) * | 2008-02-14 | 2013-04-10 | 沈阳药科大学 | 芳环并三嗪类衍生物及其应用 |
| EP2547664B1 (de) | 2010-03-16 | 2016-05-04 | Merck Patent GmbH | Morpholinylchinazoline |
-
2011
- 2011-11-18 DE DE102011118830A patent/DE102011118830A1/de not_active Withdrawn
-
2012
- 2012-10-30 SI SI201230559A patent/SI2780332T1/sl unknown
- 2012-10-30 EP EP12783121.2A patent/EP2780332B1/de active Active
- 2012-10-30 CA CA2856103A patent/CA2856103C/en active Active
- 2012-10-30 HK HK15100269.7A patent/HK1199875A1/xx unknown
- 2012-10-30 DK DK12783121.2T patent/DK2780332T3/en active
- 2012-10-30 US US14/351,773 patent/US9187469B2/en active Active
- 2012-10-30 CN CN201280056504.4A patent/CN103930408B/zh not_active Expired - Fee Related
- 2012-10-30 AU AU2012339196A patent/AU2012339196B2/en not_active Ceased
- 2012-10-30 JP JP2014541555A patent/JP6096792B2/ja not_active Expired - Fee Related
- 2012-10-30 IN IN1287KON2014 patent/IN2014KN01287A/en unknown
- 2012-10-30 MX MX2014005838A patent/MX2014005838A/es not_active Application Discontinuation
- 2012-10-30 HR HRP20160495TT patent/HRP20160495T1/hr unknown
- 2012-10-30 WO PCT/EP2012/004542 patent/WO2013072015A1/de not_active Ceased
- 2012-10-30 ES ES12783121.2T patent/ES2572605T3/es active Active
- 2012-10-30 EA EA201400595A patent/EA201400595A1/ru unknown
- 2012-10-30 BR BR112014011805A patent/BR112014011805A2/pt not_active Application Discontinuation
- 2012-10-30 PL PL12783121T patent/PL2780332T3/pl unknown
- 2012-10-30 HU HUE12783121A patent/HUE027577T2/en unknown
- 2012-10-30 KR KR1020147016518A patent/KR20140097391A/ko not_active Withdrawn
- 2012-10-30 RS RS20160351A patent/RS54768B1/sr unknown
- 2012-10-30 SG SG11201402206YA patent/SG11201402206YA/en unknown
-
2014
- 2014-05-12 IL IL232577A patent/IL232577A/en active IP Right Grant
- 2014-06-17 ZA ZA2014/04438A patent/ZA201404438B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211177T1 (hr) | Korteksolon 17alfa-valerat za uporabu u liječenju tumora | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12018500284B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| WO2015095227A3 (en) | Peptidomimetic compounds and antibody-drug conjugates thereof | |
| CL2014001792A1 (es) | Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades. | |
| JP2015500225A5 (enExample) | ||
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| WO2016161342A3 (en) | Nitrobenzyl derivatives of anti-cancer agents | |
| IL258246B (en) | Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer | |
| EA201591686A1 (ru) | Пиридинильные и конденсированные пиридинильные производные триазолона | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| NZ721500A (en) | Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury | |
| TW201613577A (en) | Pharmaceutical combinations | |
| TN2015000386A1 (en) | Formulations of organic compounds | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| JP2015507020A5 (enExample) | ||
| WO2015159155A3 (en) | Novel ademetionine formulations | |
| JP2016515550A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| WO2015035410A8 (en) | Cancer therapy | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. |